23 May 2019

Renal denervation

RADIANCE-HTN SOLO: six-month results of renal denervation in patients on medications using the ReCor Paradise endovascular ultrasound system in a randomised, blinded, sham-controlled study

Sponsored by ReCor Medical

Chairpersons: M. Azizi, F. Mahfoud

Panellists: A. Kirtane, R. Schmieder

SHOW MORE

Summary

Consult this session to learn all about the latest results from the RADIANCE-HTN SOLO cohort at the 6-month time point to assess efficacy of renal denervation in patients after medication titration.

Learning Objectives

To explore the latest results from the RADIANCE-HTN SOLO cohort at the 6-month time point to assess efficacy of renal denervation in patients after medication titration
To evaluate the potential real-world clinical benefits of renal denervation therapy in various patient subgroups
To identify future clinical initiatives needed for therapy development and initial clinical adoption

Presentations available when logged in:

RDN procedure with the ReCor Paradise technology: anatomy, treatment location, and procedure standardisation
RADIANCE-HTN SOLO: in-depth analysis at 6 months after medication titration
RADIANCE global clinical trial program - Current and upcoming clinical studies and implications for clinical adoption

Log in or create account for free

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…